Literature DB >> 971548

Effect of dopamine infusion on plasma levels of growth hormone in normal subjects and in agromegalic patients.

G Verde, G Oppizzi, G Colussi, G Cremascoli, L Botalla, E E Müller, F Silvestrini, P G Chiodini, A Liuzzi.   

Abstract

In ten normal subjects and in twenty acromegalic patients plasma levels of growth hormone were studied after administration of L-dopa and a dopamine infusion. In the ten normal subjects L-dopa, but not dopamine, increased plasma levels of GH. In the acromegalic patients both L-dopa and dopamine were followed by an inhibition of GH release. Since dopamine does not cross the blood-brain barrier, these results, although not excluding a site of action at median eminence level, support the thesis that the inhibitory effect of dopaminergic stimulation on GH release in acromegaly possibly involves receptors present on GH-secreting cells.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 971548     DOI: 10.1111/j.1365-2265.1976.tb01971.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

Review 1.  Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin.

Authors:  M F Scanlon; M Pourmand; A M McGregor; M D Rodriguez-Arnao; K Hall; A Gomez-Pan; R Hall
Journal:  J Endocrinol Invest       Date:  1979 Jul-Sep       Impact factor: 4.256

2.  Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism.

Authors:  P Price; A Debono; J D Parkes; C D Marsden; J Rosenthaler
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

3.  Increased growth hormone response to dopamine infusion in insulin-dependent diabetic subjects: indication of possible blood-brain barrier abnormality.

Authors:  M Lorenzi; J H Karam; M B McIlroy; P H Forsham
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

4.  Validity of urinary monoamine assay sales under the "spot baseline urinary neurotransmitter testing marketing model".

Authors:  Marty Hinz; Alvin Stein; Thomas Uncini
Journal:  Int J Nephrol Renovasc Dis       Date:  2011-07-20

5.  The Parkinson's disease death rate: carbidopa and vitamin B6.

Authors:  Marty Hinz; Alvin Stein; Ted Cole
Journal:  Clin Pharmacol       Date:  2014-10-21

6.  Neurotransmitter testing of the urine: a comprehensive analysis.

Authors:  Marty Hinz; Alvin Stein; George Trachte; Thomas Uncini
Journal:  Open Access J Urol       Date:  2010-10-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.